GSK said Blenrep did not meet the primary endpoint of progression-free survival, or the time in which a disease does not worsen or lead to death, when compared with a combination of pomalidomide and low doses of the steroid dexamethasone in patients with relapsed or refractory multiple myeloma.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/a3jXmqB
0 Comments